Michael Ulz: Hi guys, good afternoon and thanks for taking the question. Maybe just a quick one on KRAZATI. You mentioned sales in December were driven by inventory stocking, just curious as we think about 1Q, should we anticipate additional inventory stocking? Thanks.
Laurie Stelzer: Yes. As always with the beginning of a launch, you see as you put the product out in the channel and not all the sales in the fourth quarter in December were stocking, but a majority of it were. We’ll start to see demand really driving sales as we get into the first quarter, so more to come on that.
Operator: The next question comes from Yigal Nochomovitz at Citigroup. Please go ahead.
Yigal Nochomovitz: Hi, thank you for taking the questions. I just had a quick one on the Phase 3 strategy on first-line lung, specifically for the PD L1 greater than 50. I was reading the recent February issue of Cancer Discovery and specifically, there’s an editorial on the February 6 entitled Frontline Promise for Adagrasib Pembrolizumab Combination. And in that piece, it’s mentions that Mirati is PD L1 greater than 50 Phase 3 trial design will be ada plus pembro versus pembro. I’m just wondering if you can confirm if that is correct because I do not believe you discuss the specific design as yet. Thank you.
David Meek: Sure, so – yes I’m happy to comment on it. So, in the less 50%, of course the standard of care has been 189. And so, that’s why that study is designed with the doublet versus that triplet. In the greater than 50%, we had preliminary discussions with the FDA that monotherapy for pembrolizumab is an appropriate control arm and so therefore, the doublet would be – would go up against the pembrolizumab as you described and so – and as was mentioned in that editorial. So, that is correct.
Operator: The next question comes from Maury Raycroft at Jefferies. Please go ahead.
Maury Raycroft: Hi, thanks for taking the question. I had a question about the monotherapy confirmatory Phase 3 that KRYSTAL-12. You’ve adjusted the study to allow crossover in patients once the PFS endpoint is achieved. Would you expect in the first half ’24? Can you provide specifics on what patients are getting after they failed docetaxel in the control arm and talk more about what ultimately gives you confidence you can succeed and overall survival?
James Christensen: Yes, I think an important point for K12 is the fact of having both PFS and OS as primary endpoints and I think the important – the most important aspect of that is at the PFS is a primary endpoint that has been accepted by the FDA as a means for approval. And I think that’s important for a couple of ways because of the fact that PFS is not going to be impacted at all by crossover and it will come in much earlier than the overall survival. So, I think that’s probably the key elements of that particular study, I’d like to emphasize.
Operator: The next question comes from Evan Seigerman at BMO. Please go ahead.
Evan Seigerman: Hi guys. Thank you so much for taking the question. I wanted to touch a little bit on your commentary around potential collaborators or kind of some business development as you were highlighting. Are there any gating factors in your discussions or kind of that you need to achieve before a collaborator would come or you’d want to collaborate or to come in? And could maybe provide us some color as to how you’re thinking about potentially structure in these partnerships you out licensing. I guess I’m trying to get a sense as to how you’re going to continue the business moving forward with the launch, and with a lot of trials ongoing. Thank you so much.
